Core Viewpoint - The stock price of Valiant Bio-B (09887) increased by 7.91% to HKD 66.20, with a trading volume of HKD 28.44 million following the announcement of its inclusion in the Hang Seng Composite Index [5]. Group 1: Stock Performance - Valiant Bio-B's stock price rose by 7.91% to HKD 66.20 [5]. - The trading volume reached HKD 28.44 million [5]. Group 2: Index Inclusion - On February 13, the Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, including Valiant Bio-B in the Hang Seng Composite Index [5]. - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026 [5]. - The inclusion may lead to adjustments in the Hong Kong Stock Connect investment scope, as Valiant Bio-B meets various criteria such as market capitalization, liquidity, and listing duration [5]. Group 3: Clinical Research - Valiant Bio-B announced the successful administration of its drug, ViliXin™ (PD-L1/4-1BB bispecific antibody, LBL-024), to the first patient in an Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [5]. - The open-label, multicenter Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted at multiple hospitals nationwide [5]. - The trial aims to evaluate the efficacy and safety of ViliXin™ either as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [5].
维立志博-B午前涨逾8% 公司获纳入恒生综合指数有望入通